UA84712C2 - N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors - Google Patents

N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors

Info

Publication number
UA84712C2
UA84712C2 UAA200602943A UAA200602943A UA84712C2 UA 84712 C2 UA84712 C2 UA 84712C2 UA A200602943 A UAA200602943 A UA A200602943A UA A200602943 A UAA200602943 A UA A200602943A UA 84712 C2 UA84712 C2 UA 84712C2
Authority
UA
Ukraine
Prior art keywords
amidyl
benzimidazolyl
substituted pyrazolyl
kit inhibitors
inhibitors
Prior art date
Application number
UAA200602943A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джошуа Болджер
Арлиндо Л. Кастелано
Эндрю Филип Крю
Радослав Лауфер
Ань-Ху Ли
Смит Колин Питер Сембрук
Инчуань Суй
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of UA84712C2 publication Critical patent/UA84712C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200602943A 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors UA84712C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49676603P 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
UA84712C2 true UA84712C2 (en) 2008-11-25

Family

ID=34272512

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200602943A UA84712C2 (en) 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors

Country Status (19)

Country Link
EP (1) EP1664032B1 (OSRAM)
JP (1) JP4795237B2 (OSRAM)
KR (1) KR20060115346A (OSRAM)
CN (1) CN1839130A (OSRAM)
AP (1) AP2006003553A0 (OSRAM)
AR (1) AR045389A1 (OSRAM)
AT (1) ATE413395T1 (OSRAM)
AU (1) AU2004268948A1 (OSRAM)
BR (1) BRPI0413785A (OSRAM)
CA (1) CA2536151A1 (OSRAM)
DE (1) DE602004017623D1 (OSRAM)
IL (1) IL173616A0 (OSRAM)
IS (1) IS8320A (OSRAM)
MX (1) MXPA06002017A (OSRAM)
NO (1) NO20060665L (OSRAM)
RU (1) RU2006108791A (OSRAM)
TW (1) TW200524911A (OSRAM)
UA (1) UA84712C2 (OSRAM)
WO (1) WO2005021537A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
JP5583346B2 (ja) * 2006-01-18 2014-09-03 エルジー ハウスホールド アンド ヘルスケア リミテッド ｃ−Ｋｉｔ活性阻害剤、及び、肌美白剤
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
JPWO2012121168A1 (ja) * 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TW201534597A (zh) * 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
KR970701182A (ko) 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0846689B1 (en) 1996-12-09 2004-01-14 Pfizer Inc. Benzimidazole compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
RU2199532C2 (ru) 1997-06-27 2003-02-27 Фудзисава Фармасьютикал Ко., Лтд. Сульфонамидное соединение
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6444617B1 (en) 1998-07-28 2002-09-03 Nihon Nohyaku Co., Ltd. Fused-heterocycle dicarboxylic acid diamide derivatives or salts thereof, herbicide and usage thereof
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
JP2003528802A (ja) 1999-04-02 2003-09-30 ニューロゲン コーポレイション Ｎ−ベンゾイミダゾリルメチル−及びｎ−インドリルメチル−ベンズアミド並びにｃｒｆ調節物質としてのそれらの使用
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085372B1 (en) 1999-09-13 2004-12-22 Eastman Kodak Company Photographic material having improved color reproduction
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20020128232A1 (en) 2000-10-12 2002-09-12 Henderson Scott A. Heterocyclic angiogenesis inhibitors
AU2001297717B2 (en) 2000-12-11 2006-02-23 Amgen Inc. CXCR3 antagonists
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
WO2002069965A1 (en) 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
CA2441177A1 (en) 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process

Also Published As

Publication number Publication date
AP2006003553A0 (en) 2006-04-30
IS8320A (is) 2006-02-21
KR20060115346A (ko) 2006-11-08
EP1664032B1 (en) 2008-11-05
IL173616A0 (en) 2006-07-05
ATE413395T1 (de) 2008-11-15
EP1664032A1 (en) 2006-06-07
BRPI0413785A (pt) 2006-11-07
CN1839130A (zh) 2006-09-27
CA2536151A1 (en) 2005-03-10
AR045389A1 (es) 2005-10-26
JP4795237B2 (ja) 2011-10-19
MXPA06002017A (es) 2006-05-31
DE602004017623D1 (de) 2008-12-18
NO20060665L (no) 2006-05-16
JP2007502820A (ja) 2007-02-15
WO2005021537A1 (en) 2005-03-10
RU2006108791A (ru) 2006-07-27
AU2004268948A1 (en) 2005-03-10
TW200524911A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
GEP20105024B (en) Fused heterocyclic compound
GEP20084391B (en) Pyrazoles and methods of making and using the same
TW200738725A (en) Unsaturated mTOR inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
IL183514A0 (en) Pyrrolidine inhibitors of iap
MY141196A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
GEP20084421B (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
IL164511A0 (en) Heterocyclic compounds
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
DE602004024375D1 (de) Carboxamidderivate
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
IL164509A0 (en) Furyl compounds
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
GB0426313D0 (en) Therapeutic agents
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library